Iain Kilty

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11322026/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cigarette smoke induces proinflammatory cytokine release by activation of NF-ήB and posttranslational modifications of histone deacetylase in macrophages. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2006, 291, L46-L57.	2.9	414
2	Oxidative stress and cigarette smoke alter chromatin remodeling but differentially regulate NFâ€₽B activation and proinflammatory cytokine release in alveolar epithelial cells. FASEB Journal, 2004, 18, 1897-1899.	0.5	286
3	Defective bacterial phagocytosis is associated with dysfunctional mitochondria in COPD macrophages. European Respiratory Journal, 2019, 54, 1802244.	6.7	86
4	PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor. ACS Chemical Biology, 2019, 14, 1235-1242.	3.4	76
5	Differential characteristics of human 15-lipoxygenase isozymes and a novel splice variant of 15S-lipoxygenase. FEBS Journal, 1999, 266, 83-93.	0.2	55
6	Opsonic Phagocytosis in Chronic Obstructive Pulmonary Disease Is Enhanced by Nrf2 Agonists. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 739-750.	5.6	53
7	Differential Effects of p38, MAPK, PI3K or Rho Kinase Inhibitors on Bacterial Phagocytosis and Efferocytosis by Macrophages in COPD. PLoS ONE, 2016, 11, e0163139.	2.5	49
8	Chronic Obstructive Pulmonary Disease-Specific Gene Expression Signatures of Alveolar Macrophages as well as Peripheral Blood Monocytes Overlap and Correlate with Lung Function. Respiration, 2011, 81, 499-510.	2.6	46
9	Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin. Journal of Medicinal Chemistry, 2017, 60, 767-786.	6.4	45
10	Gene Expression and Immunolocalization of 15-Lipoxygenase Isozymes in the Airway Mucosa of Smokers with Chronic Bronchitis. American Journal of Respiratory Cell and Molecular Biology, 2002, 27, 666-677.	2.9	42
11	Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects. Arthritis Research and Therapy, 2019, 21, 269.	3.5	39
12	The Interleukinâ€1 Receptor–Associated Kinase 4 Inhibitor PFâ€06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial. Arthritis and Rheumatology, 2021, 73, 2206-2218.	5.6	39
13	TAK1 selective inhibition: state of the art and future opportunities. Future Medicinal Chemistry, 2015, 7, 23-33.	2.3	28
14	Glycogen synthase kinase-3β modulation of glucocorticoid responsiveness in COPD. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 309, L1112-L1123.	2.9	21
15	Stepwise Distributed Open Innovation Contests for Software Development: Acceleration of Genome-Wide Association Analysis. GigaScience, 2017, 6, 1-10.	6.4	16
16	<scp>TAK</scp> 1 Inhibition in the <scp>DFG</scp> â€Out Conformation. Chemical Biology and Drug Design, 2013, 82, 500-505.	3.2	15